213 related articles for article (PubMed ID: 37088858)
1. Repurposing the K
Lee RD; Chen YJ; Nguyen HM; Singh L; Dietrich CJ; Pyles BR; Cui Y; Weinstein JR; Wulff H
Transl Stroke Res; 2024 Jun; 15(3):518-532. PubMed ID: 37088858
[TBL] [Abstract][Full Text] [Related]
2. Repurposing the KCa3.1 inhibitor senicapoc for Alzheimer's disease.
Jin LW; Lucente JD; Nguyen HM; Singh V; Singh L; Chavez M; Bushong T; Wulff H; Maezawa I
Ann Clin Transl Neurol; 2019 Apr; 6(4):723-738. PubMed ID: 31019997
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the potassium channel K
Staal RGW; Khayrullina T; Zhang H; Davis S; Fallon SM; Cajina M; Nattini ME; Hu A; Zhou H; Poda SB; Zorn S; Chandrasena G; Dale E; Cambpell B; Biilmann Rønn LC; Munro G; Mӧller T
Eur J Pharmacol; 2017 Jan; 795():1-7. PubMed ID: 27876619
[TBL] [Abstract][Full Text] [Related]
4. Senicapoc: Repurposing a Drug to Target Microglia K
Staal RGW; Weinstein JR; Nattini M; Cajina M; Chandresana G; Möller T
Neurochem Res; 2017 Sep; 42(9):2639-2645. PubMed ID: 28364331
[TBL] [Abstract][Full Text] [Related]
5. Anti-steatotic and anti-fibrotic effects of the KCa3.1 channel inhibitor, Senicapoc, in non-alcoholic liver disease.
Paka L; Smith DE; Jung D; McCormack S; Zhou P; Duan B; Li JS; Shi J; Hao YJ; Jiang K; Yamin M; Goldberg ID; Narayan P
World J Gastroenterol; 2017 Jun; 23(23):4181-4190. PubMed ID: 28694658
[TBL] [Abstract][Full Text] [Related]
6. The potassium channel KCa3.1 constitutes a pharmacological target for neuroinflammation associated with ischemia/reperfusion stroke.
Chen YJ; Nguyen HM; Maezawa I; Grössinger EM; Garing AL; Köhler R; Jin LW; Wulff H
J Cereb Blood Flow Metab; 2016 Dec; 36(12):2146-2161. PubMed ID: 26661208
[TBL] [Abstract][Full Text] [Related]
7. KCa 3.1-a microglial target ready for drug repurposing?
Dale E; Staal RG; Eder C; Möller T
Glia; 2016 Oct; 64(10):1733-41. PubMed ID: 27121595
[TBL] [Abstract][Full Text] [Related]
8. KCa3.1 Channel Modulators as Potential Therapeutic Compounds for Glioblastoma.
Brown BM; Pressley B; Wulff H
Curr Neuropharmacol; 2018; 16(5):618-626. PubMed ID: 28676010
[TBL] [Abstract][Full Text] [Related]
9. The KCa3.1 blocker TRAM-34 reduces infarction and neurological deficit in a rat model of ischemia/reperfusion stroke.
Chen YJ; Raman G; Bodendiek S; O'Donnell ME; Wulff H
J Cereb Blood Flow Metab; 2011 Dec; 31(12):2363-74. PubMed ID: 21750563
[TBL] [Abstract][Full Text] [Related]
10. Targeting K
Todesca LM; Maskri S; Brömmel K; Thale I; Wünsch B; Koch O; Schwab A
Cell Physiol Biochem; 2021 May; 55(S3):131-144. PubMed ID: 34043300
[TBL] [Abstract][Full Text] [Related]
11. The Clinically Tested Gardos Channel Inhibitor Senicapoc Exhibits Antimalarial Activity.
Tubman VN; Mejia P; Shmukler BE; Bei AK; Alper SL; Mitchell JR; Brugnara C; Duraisingh MT
Antimicrob Agents Chemother; 2016 Jan; 60(1):613-6. PubMed ID: 26459896
[TBL] [Abstract][Full Text] [Related]
12. Erythrocytes from hereditary xerocytosis patients heterozygous for KCNN4 V282M exhibit increased spontaneous Gardos channel-like activity inhibited by senicapoc.
Rivera A; Vandorpe DH; Shmukler BE; Gallagher DR; Fikry CC; Kuypers FA; Brugnara C; Snyder LM; Alper SL
Am J Hematol; 2017 Jun; 92(6):E108-E110. PubMed ID: 28295477
[No Abstract] [Full Text] [Related]
13. Conditional KCa3.1-transgene induction in murine skin produces pruritic eczematous dermatitis with severe epidermal hyperplasia and hyperkeratosis.
Lozano-Gerona J; Oliván-Viguera A; Delgado-Wicke P; Singh V; Brown BM; Tapia-Casellas E; Pueyo E; Valero MS; Garcia-Otín ÁL; Giraldo P; Abarca-Lachen E; Surra JC; Osada J; Hamilton KL; Raychaudhuri SP; Marigil M; Juarranz Á; Wulff H; Miura H; Gilaberte Y; Köhler R
PLoS One; 2020; 15(3):e0222619. PubMed ID: 32150577
[TBL] [Abstract][Full Text] [Related]
14. The potassium channel KCa3.1 constitutes a pharmacological target for astrogliosis associated with ischemia stroke.
Yi M; Wei T; Wang Y; Lu Q; Chen G; Gao X; Geller HM; Chen H; Yu Z
J Neuroinflammation; 2017 Oct; 14(1):203. PubMed ID: 29037241
[TBL] [Abstract][Full Text] [Related]
15. Co-staining of K
Brömmel K; Maskri S; Bulk E; Pethő Z; Rieke M; Budde T; Koch O; Schwab A; Wünsch B
ChemMedChem; 2020 Dec; 15(24):2462-2469. PubMed ID: 33043595
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia.
Ataga KI; Smith WR; De Castro LM; Swerdlow P; Saunthararajah Y; Castro O; Vichinsky E; Kutlar A; Orringer EP; Rigdon GC; Stocker JW;
Blood; 2008 Apr; 111(8):3991-7. PubMed ID: 18192510
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of the K
Organ L; Bacci B; Koumoundouros E; Kimpton WG; Samuel CS; Nowell CJ; Bradding P; Roach KM; Westall G; Jaffar J; Snibson KJ
Am J Respir Cell Mol Biol; 2017 Apr; 56(4):539-550. PubMed ID: 28060543
[TBL] [Abstract][Full Text] [Related]
18. Haemoglobin response to senicapoc in patients with sickle cell disease: a re-analysis of the Phase III trial.
Ataga KI; Staffa SJ; Brugnara C; Stocker JW
Br J Haematol; 2021 Mar; 192(5):e129-e132. PubMed ID: 33527340
[No Abstract] [Full Text] [Related]
19. The potassium channel KCa3.1 represents a valid pharmacological target for microgliosis-induced neuronal impairment in a mouse model of Parkinson's disease.
Lu J; Dou F; Yu Z
J Neuroinflammation; 2019 Dec; 16(1):273. PubMed ID: 31878950
[TBL] [Abstract][Full Text] [Related]
20. Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapoc (ICA-17043).
Ataga KI; Reid M; Ballas SK; Yasin Z; Bigelow C; James LS; Smith WR; Galacteros F; Kutlar A; Hull JH; Stocker JW;
Br J Haematol; 2011 Apr; 153(1):92-104. PubMed ID: 21323872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
